BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,060,000 shares, a growth of 70.6% from the October 15th total of 621,400 shares. Based on an average daily trading volume, of 303,100 shares, the short-interest ratio is presently 3.5 days.

BioLineRx Trading Up 1.3 %

Shares of NASDAQ BLRX traded up $0.01 during midday trading on Wednesday, reaching $0.44. 84,892 shares of the company were exchanged, compared to its average volume of 347,115. BioLineRx has a one year low of $0.39 and a one year high of $1.93. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The stock’s 50-day moving average price is $0.52 and its 200-day moving average price is $0.62.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $5.39 million for the quarter, compared to analyst estimates of $3.93 million. As a group, research analysts predict that BioLineRx will post -0.03 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on BLRX. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of BioLineRx in a research note on Wednesday, November 6th. StockNews.com assumed coverage on shares of BioLineRx in a report on Friday, November 8th. They issued a “hold” rating for the company.

Hedge Funds Weigh In On BioLineRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. PVG Asset Management Corp purchased a new position in shares of BioLineRx during the second quarter valued at approximately $70,000. Atria Investments Inc increased its position in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC purchased a new stake in BioLineRx in the second quarter worth $462,000. 1.56% of the stock is owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.